Page 4 - Dr Stephanie Seneff - Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID - 19

and Pfizer trials were deemed to be SARS-CoV-1-positive at baseline despite prior infection being
grounds for exclusion. For these and other reasons the interim efficacy estimate of around 95% for
both vaccines is suspect.

A more recent analysis looked specifically at the issue of relative vs. absolute risk reduction. While
the high estimates of risk reduction are based upon relative risks, the absolute risk reduction is a
more appropriate metric for a member of the general public to determine whether a vaccination
provides a meaningful risk reduction personally. In that analysis, utilizing data supplied by the
vaccine makers to the FDA, the Moderna vaccine at the time of interim analysis demonstrated an
absolute risk reduction of 1.1% (p= 0.004), while the Pfizer vaccine absolute risk reduction was
0.7% (p<0.000) (Brown 2021).

Others have brought up important additional questions regarding COVID-19 vaccine development,
questions with direct relevance to the mRNA vaccines reviewed here. For example, Haidere, et. al.
(2021) identify four “critical questions” related to development of these vaccines, questions that are
germane to both their safety and their efficacy:

• Will Vaccines Stimulate the Immune Response?
• Will Vaccines Provide Sustainable Immune Endurance?
• How Will SARS-CoV-2 Mutate?
• Are We Prepared for Vaccine Backfires?

Lack of standard and extended preclinical and clinical trials of the two implemented mRNA vaccines
leaves each of these questions to be answered over time. It is now only through observation of
pertinent physiological and epidemiological data generated by widescale delivery of the vaccines to
the general public that these questions will be resolved. And this is only possible if there is free
access to unbiased reporting of outcomes -- something that seems unlikely given the widespread
censorship of vaccine-related information because of the perceived need to declare success at all
cost.
The two mRNA vaccines that have made it through phase 3 trials and are now being delivered to
the general population are the Moderna vaccine and the Pfizer-BioNTech vaccine. The vaccines
have much in common. Both are based on mRNA encoding the spike protein of the SARS-CoV-2
virus. Both demonstrated a relative efficacy rate of 94-95%. Preliminary indications are that
antibodies are still present after three months. Both recommend two doses spaced by three or four
weeks, and recently there are reports of annual booster injections being necessary (Mahose, 2021).
Both are delivered through muscle injection, and both require deep-freeze storage to keep the RNA
from breaking down. This is because, unlike double-stranded DNA which is very stable, single-
strand RNA products are apt to be damaged or rendered powerless at warm temperatures and must
be kept extremely cold to retain their potential efficacy (Pushparajah et al., 2021). It is claimed by the
manufacturers that the Pfizer vaccine requires storage at -94 degrees Fahrenheit (-70 degrees
Celsius), which makes it very challenging to transport it and keep it cold during the interim before it
is finally administered. The Moderna vaccine can be stored for 6 months at -4 degrees Fahrenheit (-
20 degrees Celsius), and it can be stored safely in the refrigerator for 30 days following thawing
(Zimmer et al., 2021).

International Journal of Vaccine Theory, Practice, and Research 2(1), May 10, 2021 Page | 392